Phreesia, Inc. - PHR STOCK NEWS

Phreesia announces that David Linetsky, SVP of Life Sciences, has been recognized as one of the 2021 PM360 ELITE 100 for his transformative contributions in healthcare. Chosen from over 500 candidates, Linetsky's leadership in restructuring the Life Sciences department and launching PatientInsights has significantly impacted patient engagement. His efforts during the COVID-19 pandemic also included co-authoring reports highlighting the effects on outpatient visits. Linetsky expressed pride in his team’s work and the potential of Phreesia’s technologies.

Phreesia, Inc. (NYSE: PHR) is set to hold a conference call on June 4, 2021, at 8:30 a.m. Eastern Time to discuss its fiscal Q1 2022 financial results. The press release detailing these results will be issued after market close on June 3, 2021. The company specializes in providing healthcare organizations with a suite of applications designed to enhance patient intake processes, thereby improving clinical care and operational efficiency.

Phreesia has partnered with the Ad Council and the Alzheimer’s Association to enhance awareness of Alzheimer’s disease through targeted public service announcements. In the initial 10 weeks, nearly 90,000 patients and caregivers engaged with the campaign, with over 1,500 completing a survey. Results indicated that those exposed to the campaign were more than 25% likely to recognize Alzheimer's symptoms. Notably, 52% of engaged patients expressed intentions to discuss Alzheimer’s with their healthcare providers. The campaign aims to promote early diagnosis, crucial for better outcomes in managing the disease.

Phreesia, Inc. (NYSE:PHR) has successfully completed a public offering of 5,175,000 shares of common stock at $50.00 per share, generating approximately $245.3 million in net proceeds after deducting underwriting discounts and expenses. The offering included a full exercise of the underwriters' option for an additional 675,000 shares. J.P. Morgan and William Blair served as joint book-running managers, with several firms acting as co-managers. The offering is conducted under an effective shelf registration statement filed with the SEC.

Phreesia (NYSE:PHR) has priced its public offering of 4,500,000 shares at $50.00 each, aiming for net proceeds of approximately $213.2 million. An additional 675,000 shares can be purchased by underwriters. The offering is set to close on April 12, 2021, subject to customary conditions. The company intends to use the funds raised to enhance its patient intake management platform, which aims to improve efficiency in healthcare organizations. Financial representatives include J.P. Morgan and William Blair.

Phreesia, Inc. (NYSE: PHR) has initiated an underwritten public offering of 4,500,000 shares of its common stock. Additionally, underwriters may acquire up to 675,000 shares more within 30 days. This offering is subject to market conditions and the actual size may vary. J.P. Morgan and William Blair are the joint book-running managers, with Allen & Company LLC and Piper Sandler as passive book-running managers. The offering will be made via a prospectus supplement and is compliant with SEC regulations.

Phreesia, Inc. (NYSE: PHR) reported its financial results for the fiscal fourth quarter and year ending January 31, 2021. The company achieved a 27% year-over-year revenue increase to $41.8 million for Q4 and a 19% increase to $148.7 million for the fiscal year. However, adjusted EBITDA for Q4 turned negative at $0.09 million, down from $1.3 million the previous year, and cash reserves decreased by $35.3 million to $218.8 million. Looking ahead, Phreesia projects revenue growth between $178 million and $186 million for fiscal 2022, maintaining previous growth guidance.

Phreesia has partnered with New Jersey Urology (NJU) to enhance the patient intake process across over 60 locations in New Jersey. This collaboration aims to improve operational efficiency and patient experience, utilizing Phreesia's integrated platform within Epic’s system. Key achievements over the first 120 days include:

• 40,600 patients completed outcomes
• 54% registered before visits
• 84% copays paid at service
• 87% positive ratings of check-in

This integration is expected to support patient-focused care while minimizing in-person exposure.

Phreesia has partnered with the CONVINCE USA initiative at CUNY Graduate School of Public Health to develop a patient survey aimed at understanding COVID-19 vaccine hesitancy. Over 300,000 responses have been collected, highlighting disparities; 78% of those 65 and older are likely to vaccinate, versus less than half of essential workers. The survey equips providers with patient data to address concerns during visits. This initiative is part of Phreesia's Vaccine Management Solution, aiming to enhance vaccine access and education in vulnerable communities.